Intense Simplified Strategy for Type 2 Diabetes Management
Study Overview
This study aimed to see if a new treatment approach could help patients newly diagnosed with type 2 diabetes and high blood sugar levels. The approach includes a short period of intensive insulin therapy followed by oral medications.
Study Details
- Design: A multicentre, open label, randomised trial.
- Location: 15 hospitals in China from December 2017 to December 2020.
- Participants: 412 patients with high blood sugar (HbA1c ≥8.5%).
- Interventions: Participants received 2-3 weeks of intensive insulin therapy, followed by different oral treatments or lifestyle changes for 48 weeks.
Main Findings
The main goal was to see how many participants achieved a target HbA1c level of less than 7.0% after 48 weeks. Here are the results:
- Success Rates:
- 80% of the linagliptin plus metformin group
- 72% of the linagliptin group
- 73% of the metformin group
- 60% of the control group
- Lower HbA1c Levels:
- 70% of the linagliptin plus metformin group achieved HbA1c <6.5%
- Compared to 48% in the control group
- Improved Outcomes: The linagliptin plus metformin group showed the best results overall, including better fasting glucose levels.
Conclusion
The study concluded that the intense strategy, particularly the combination of linagliptin and metformin, effectively improved blood sugar control in patients with newly diagnosed type 2 diabetes. This approach can guide better management decisions for diabetes care.
Additional Information
Clinical trials are essential for creating safe treatments. Our AI platform, DocSym, helps healthcare professionals by providing a comprehensive knowledge base that combines clinical guidelines and research.
In today’s healthcare setting, it’s vital to improve efficiency. Our mobile apps assist in scheduling, treatment monitoring, and telemedicine, enhancing patient care and expanding services.
By integrating AI, clinics can streamline operations, improve patient outcomes, and reduce paperwork. Discover more at aidevmd.com.
